替莫唑胺联合替尼泊苷治疗恶性胶质细胞瘤的临床疗效分析  

An Analysis of the Clinical Efficacy of Temozolomide Combined with Teniposide in the Treatment of Glioblastoma

作　　者：颜建辉 梁永 王家祺 刘超 欧阳松 唐红宇 

机构地区：[1]长沙市第一医院神经内科,湖南长沙410001

出　　处：《肿瘤药学》2014年第3期207-210,共4页Anti-Tumor Pharmacy

基　　金：长沙市科技计划项目(编号:K1109033-31)

摘　　要：目的探讨替莫唑胺联合替尼泊苷治疗恶性胶质细胞瘤的临床疗效及安全性。方法将我院2009年5月至2013年6月收治的确诊为脑恶性胶质瘤的90例患者随机分为治疗组和对照组,每组45例。治疗组给予替莫唑胺加替尼泊苷联合治疗,对照组单独给予替莫唑胺治疗,观察比较两组的总有效率、疾病控制率及不良反应的发生情况。结果治疗组和对照组的总有效率分别为64.4%和42.2%,疾病控制率分别为84.4%和62.2%,治疗组均显著高于对照组(P<0.05)。治疗组恶心、呕吐、白细胞减少和肝肾毒性等不良反应发生率均明显低于对照组(P<0.05)。结论与单用替莫唑胺治疗相比,替莫唑胺联合替尼泊苷治疗胶质母细胞瘤的疗效更好,安全性更高,值得在临床上推广。Objective To explore the clinical effects of temozolomide combined with teniposide in the treatment of glioblas-toma. Methods Ninety cases that were diagnosed of brain malignant glioma patients between May 2009 and June 2013 in our hospital were divided randomly into treating group （n=45） and control group （n=45）, the treating group was given temozolomide combined with teniposider, while the control group only treated with temozolomide. The total effective rate, disease control rate and the adverse reaction incidence between the two groups were observed and compared. Results The total effective rate was higher in the treating group （64.4%） than in the control group （42.2%）, with statistical significance （P〈0.05）. The disease con-trol rate was 84.4%in the treating group, significantly higher than that （62.2%） in the control group （P〈0.05）. The incidences of nausea and vomiting, hypoleucocytosis, liver and kidney toxicity were significantly lower in the treating group than in the control group （P〈0.05）. Conclusions The temozolomide combined with teniposide had better clinical effects than simple temozolomide in the treatment of glioblastoma, and deserve popularization in clinic.

关 键 词：恶性胶质细胞瘤 替莫唑胺 替尼泊苷 临床疗效 安全性 

分 类 号：R739.65[医药卫生—肿瘤]